Clinical Trials Brief | July 27, 2026
This week: WHO consulting on its first full rewrite of the 1995 GCP guideline, aligned with ICH E6(R3), FDA approving GSK's zidesamtinib two months early on a single-arm trial, CHMP recommending twelve new medicines including the first oral IL-23 receptor blocker, an FDA advisory committee overriding agency staff to back compounding of unapproved peptides, and Repligen buying the company whose cell-therapy preservation media sit inside many of today's trials.
WHO consults on a full rewrite of its 1995 GCP guideline, aligned with ICH E6(R3) and built for countries outside ICH
What changed
WHO has published for public consultation a draft revision of its Guidelines for Good Clinical Practice for Trials on Pharmaceutical Products, the first full update since the original 1995 guideline, which it will replace. The draft is dated June 2026 and was circulated and covered by quality and GCP organisations in late July. Comments are open until 6 September 2026. It has three parts that are meant to be read together: the main principles; Annex 1, setting out detailed requirements with supporting appendices; and Annex 2, covering trials with decentralised elements, pragmatic elements and/or real-world data. According to the GMP-Compliance summary, the core principles are aligned with ICH E6(R3), and WHO will provide its own modular implementation guidance to help countries apply the standards in different regulatory settings, supporting convergence and reliance while respecting national autonomy.
Why it matters
ICH E6(R3) applies directly in ICH member regions, but many countries that host multinational trials are not ICH members and rely on WHO guidance as their reference. A WHO text aligned with E6(R3) narrows the gap between "ICH GCP" and "local GCP" that sponsors currently manage country by country, particularly in Africa, Latin America and parts of Asia. The structure mirrors E6(R3) almost one-to-one, including a separate annex for decentralised and real-world-data trials, only weeks after ICH finalised its own Annex 2. In my reading, the reliance language matters as much as the GCP content: it signals that WHO wants national regulators to be able to lean on each other's inspections and decisions.
Takeaway
Sponsors and CROs running trials in non-ICH countries should review the draft before 6 September, especially the implementation modules, because those are what national authorities are likely to copy into local requirements. Quality teams can expect the familiar E6(R3) concepts (risk proportionality, critical-to-quality factors, oversight of service providers) to become the global baseline over the next few years.
Sources
This item is grounded in the WHO draft documents (QAS/26.995) and summaries from GMP-Compliance and the Research Quality Association. I could not confirm the exact date WHO first posted the draft.
FDA approves zidesamtinib two months ahead of its PDUFA date, on a 117-patient single-arm trial
What changed
On July 22, 2026, FDA approved Jideytro (zidesamtinib, GSK) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor. The approval came ahead of the September 18, 2026 target action date and follows Breakthrough Therapy and Orphan Drug designations. It is based on the global single-arm Phase 1/2 ARROS-1 trial, specifically 117 patients previously treated with a ROS1 inhibitor. Targeted Oncology and OncLive reported an objective response rate of 44% (95% CI, 34%-53%), duration-of-response rates of 82% at 6 months and 69% at 12 months, and responses in 21 of 42 patients (50%) with ROS1 resistance mutations. GSK completed its $10.6 billion acquisition of Nuvalent on July 15, so this is GSK's first approved medicine in lung cancer. ARROS-1 continues, including in patients who have not had a ROS1 inhibitor.
Why it matters
This closes the loop on the deal this brief covered on June 15: GSK paid for an asset with an FDA action date, and the approval arrived two months early, a week after closing. On evidence standards, it shows that single-arm trials remain acceptable in molecularly defined oncology settings with a clear unmet need and durable responses, even as FDA's new draft guidance on substantial evidence states a preference for clinical endpoints and puts more weight on well-controlled designs. The resistance-mutation data matter clinically, because overcoming on-target resistance after earlier ROS1 inhibitors is the main reason next-generation agents exist.
Takeaway
Precision-oncology sponsors should not read the June substantial-evidence draft as the end of single-arm pathways in rare molecular subsets. They should expect FDA to look closely at response durability, intracranial activity and resistance-mutation subgroups. Neladalkib, Nuvalent's ALK inhibitor, has a November 27 target date and will be the next test.
Sources
This item is grounded in GSK's press release of July 22, 2026 and reporting by Targeted Oncology and OncLive.
CHMP recommends twelve new medicines, including the first oral IL-23 receptor blocker, and issues three negative opinions
What changed
At its July 20-23, 2026 meeting, CHMP recommended twelve new medicines and eight extensions of indication. New recommendations include Icotyde (icotrokinra), the first oral medicine targeting the interleukin-23 receptor, for moderate-to-severe plaque psoriasis in adults and adolescents from 12 years; Susvimo, a surgically implanted, refillable ranibizumab reservoir for wet AMD, the first of its kind in the EU, refilled every six months; three lipid-lowering medicines (lerodalcibep, obicetrapib, and obicetrapib with ezetimibe); linerixibat for cholestatic pruritus in primary biliary cholangitis; leriglitazone, under exceptional circumstances, for cerebral adrenoleukodystrophy; and ensitrelvir for COVID-19 post-exposure prophylaxis. CHMP adopted negative opinions for KemSu (sufentanil/ketamine) for acute pain in children aged 1 to under 18, Meplyffa (arimoclomol) for Niemann-Pick type C, and Qezzaqar (catequentinib) for synovial sarcoma or leiomyosarcoma. Omeros and MaaT Pharma requested re-examination of the June negative opinions on Yartemlea and Xervyteg. CHMP also endorsed XFG-adapted compositions for four COVID-19 vaccines.
Why it matters
Icotrokinra is the headline for trial design: an oral peptide that blocks a target previously reached only by injectable antibodies. If it holds up in practice, it changes the comparator landscape for every psoriasis and IBD programme, because "oral versus injectable biologic" becomes a head-to-head question rather than a convenience argument. The KemSu refusal is also worth noting. It shows that a paediatric-specific formulation of two known agents does not get an easy path when the benefit-risk balance in children is not clearly established.
Takeaway
Dermatology and immunology sponsors planning Phase 3 programmes for 2027 should expect EU regulators and HTA bodies to ask about oral IL-23R blockade as a relevant comparator. The three CHMP negative opinions are worth reading in full: the question-and-answer documents usually spell out what evidence was missing, which is directly useful for protocol design.
Sources
This item is grounded in EMA's CHMP meeting highlights for July 20-23, 2026, published July 24.
An FDA advisory committee overrides agency staff and backs compounding of six unapproved peptides, including BPC-157
What changed
On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six of seven reviewed peptides to the 503A Bulks List, which allows state-licensed compounding pharmacies to prepare them for individual patients without further agency review. BPC-157 (nominated for ulcerative colitis) and KPV (wound treatment and inflammatory conditions) were backed on day one by 8-6 with one abstention, according to RAPS. On day two, the committee backed epitalon (7-5, one abstention) and semax and rejected emideltide. HealthDay, citing STAT, reported that FDA staff recommended rejecting every peptide because of a lack of clinical evidence on safety or effectiveness. RAPS reported that FDA had added several temporary voting members to the committee earlier that week. HHS Secretary Robert F. Kennedy Jr. has publicly supported easing peptide restrictions. The votes are not binding, and FDA makes the final decision.
Why it matters
None of these peptides are approved drugs, and most are injected. NPR noted that once a substance is on the bulks list, prescribers are not limited to the indication used to nominate it. According to RAPS, many of these peptides were restricted from compounding after a 2023 reclassification. In practice, a positive FDA decision would create legal, pharmacy-supplied access to products with little controlled-trial evidence, and adverse events would mainly reach FDA through spontaneous reporting from compounding settings, which is a weak surveillance channel. It is also unusual for an advisory panel to vote against FDA staff across almost the whole agenda.
Takeaway
For clinical trial teams, the immediate impact is on concomitant medications. Expect more participants using compounded peptides, often bought through wellness clinics, and make sure screening questions and prohibited-medication lists capture them explicitly. If FDA adopts the recommendations, sponsors developing approved peptide therapeutics in the same indications will also face recruitment competition from compounded alternatives.
Sources
This item is grounded in RAPS reporting of July 23 and 24, 2026, NPR, and HealthDay (citing STAT and The New York Times).
Repligen agrees to buy BioLife Solutions for about $1.5 billion, consolidating a key supplier to cell-therapy trials
What changed
On July 22, 2026, Repligen announced a definitive agreement, dated July 21, to acquire BioLife Solutions for a total enterprise value of approximately $1.5 billion. BioLife shareholders will receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share. The deal is expected to close in the fourth quarter of 2026, subject to BioLife shareholder approval, antitrust clearance and other conditions. BioLife makes cell-processing tools for cell therapy, led by its CryoStor biopreservation media, which Repligen said support a number of approved cell therapies and many clinical trials. In its subsequent second-quarter report, BioLife said its biopreservation media are used in about 250 ongoing commercially sponsored US clinical trials, which it puts at more than 70% market share, including over 30 Phase 3 trials.
Why it matters
This is a supply-chain story more than a pipeline story. Cryopreservation media are specified in a cell therapy's manufacturing process and regulatory filings, so switching supplier mid-development generally requires comparability work. When one supplier holds most of the market, its ownership, pricing and continuity of supply become a quiet risk for a large share of cell and gene therapy trials. The same week, Novartis agreed to acquire UK ADC developer Myricx Bio for up to $1.5 billion, according to Drug Discovery World, a reminder that July's deal flow ran through both tools and therapeutics.
Takeaway
Sponsors of cell therapy programmes should check their critical-materials risk assessments. If a single biopreservation supplier is specified for a product heading into Phase 3 or commercial supply, change-of-control events like this are the moment to confirm supply agreements and dual-sourcing plans. For quality teams, the item belongs in supplier qualification and change-notification tracking.
Sources
This item is grounded in Repligen and BioLife SEC filings of July 22-23, 2026 and BioLife's second-quarter 2026 report.